PubMed Health⌕ Search

Biomedical subjects

M Sessarego

Publications and source records attributed to M Sessarego.

124 records · Page 7Linked to original sources
PubMed1981

Marrow colony stimulating activity in chronic myelogenous leukemia.

Colony stimulating activity (CSA) from bone marrow adherent cells was tested in various myeloproliferative disorders in comparison with chronic myelogenous leukemia (CML). A higher level of medullary CSA was found in acute leukemias with monoblastic component, as contrasted with low values in other acute non lymphocytic leukemias (ANLL). In CML, while the majority of patients had CSA values within normal interval, few patients had consistently higher level of this activity. Comparative analysis of growth pattern in agar or in liquid culture suggests that significant increase in medullary CSA production can be related to an abnormal regulation of granulopoiesis.

Bone Marrow↗
PubMed1980

Preparation of colony stimulating activity from human leukemic urine: hydrophobic chromatography on propylamine-agarose.

Urinary colony stimulating factor (CSF) from human leukemic urine is retained on propylamine-agarose hydrophobic chromatography; about 70% of total activity is eluted by the addition of 1 M NaCl with significant increase in specific activity. Incomplete binding of urinary CSF to this resin further confirm that biological activity is a heterogeneous pool of different molecular species. Analysis of the macro- and microscopic composition of colonies indicates that CSF resulting from this purification step maintains the ability to stimulate both granulocytic and macrophage progenitors.

Chromatography, Agarose↗
PubMed1979

Composition of human granulocytic colonies as a function of the purification stage of CSF.

Granulopoietic colonies grown in presence of human placental conditioned medium (HPCM), before and after partial purification, were characterized in terms of number of colonies, colony size and cellular composition. Our data demonstrate that the removal of inhibitors present in crude HPCM preparations results in a higher number of CFUC which are wider in size and with different cellular composition.

Bone Marrow Cells↗
PubMedDate not supplied

Cytogenetics of infantile leukemias and its correlations with bio-clinical features. The "G. Gaslini" Children's Hospital experience over a 9-year period.

BACKGROUND AND METHODS: Infantile leukemia is a rare disorder, and few cytogenetic studies have been performed on this condition. RESULTS AND CONCLUSIONS: The authors present the cytogenetic analyses performed on 14 cases of infantile leukemia. The most frequent chromosomal changes are rearrangements involving 11q (4 cases) and gains of one or more chromosomes 21. Patients with chromosomal rearrangements show a worse prognosis than those with only hyperdiploidy or a normal karyotype, although the difference was not statistically significant due to the small size and short median follow-up.

Chromosome Aberrations↗
PubMedDate not supplied

Clonality study by fluorescence in situ hybridization of a patient with refractory anemia with ringed sideroblasts and monosomy 7.

Myelodysplastic syndromes (MDS) are stem cell diseases but it is still controversial whether chromosomal abnormalities occurring in these disorders affect a multipotent stem cell or a committed progenitor. We studied a case of refractory anemia with ringed sideroblasts (RARS) and monosomy 7 in 100% of examined metaphases. Using the fluorescence in situ hybridization (FISH) technique with a probe specific for the centromeric region of chromosome 7, we demonstrated that 15% of BM cells fixed in acetic acid/methanol exhibited a normal diploid karyotype. Applying the FISH technique on PB cells smeared onto a slide, we observed that lymphocytes maintain two chromosomes 7, whereas other leukocytes exhibited monosomy 7. Our study confirms that chromosomal abnormalities found in MDS can occur in cells capable of differentiation along granulocytic and monocytic lineages, but not along the lymphocytic lineage.

Anemia, Sideroblastic↗
PubMedDate not supplied

Cytogenetic abnormalities in patients with severe aplastic anemia.

BACKGROUND: Cytogenetic abnormalities have been described in a few patients with otherwise typical severe aplastic anemia (SAA), and the possible clonal nature of this disease is a controversial issue. MATERIALS AND METHODS: Sixty-nine patients with acquired severe aplastic anemia underwent cytogenetic examination on bone marrow cells at the time of diagnosis (n = 34) and/or at least twice after immunosuppressive therapy (IS) (n = 35). RESULTS: We identified 2 major groups. Group A: 51 patients (74%) were normal and remained normal. Group B: 18 patients (26%) had at least one abnormal cytogenetic analysis. This second group could be further subdivided as follows: (B1) chromosomal abnormalities not present at first examination and acquired in the course of the disease (n = 7); (B2) clonal cytogenetic abnormalities present at first examination and persisting (n = 3); (B3) reversible cytogenetic abnormalities (n = 8). The most frequent abnormality was trisomy 8 (n = 8) followed by monosomy 7 (n = 2); 82% of patients are alive in group A and 61% in group B. Three patients developed acute leukemia, all from group B. This represents 4% of all patients or 17% of those with at least one abnormal cytogenetic test. CONCLUSIONS: Thus the majority of SAA patients have normal karyotypes in marrow cells at presentation and at follow-up. Patients with abnormal karyotypes exist and can be further subdivided into those with reversible and those with persistent abnormalities. The latter are at risk of developing myelodysplasia or acute leukemia.

Adolescent↗
PubMedDate not supplied

High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.

BACKGROUND: Elderly patients with acute myeloid leukemia (AML) those refractory to induction chemotherapy and those with so-called secondary leukemia have unfavorable prognoses and require innovative therapeutic approaches. Fludarabine allows an increased accumulation of Ara-CTP in leukemic cells and inhibits DNA repair mechanisms; therefore its association with Ara-C and mitoxantrone results in a synergistic effect. MATERIALS AND METHODS: From May 1993 to February 1996, fludarabine-containing regimens (FLAG and FLANG) were employed as induction therapy in 51 high-risk AML patients. Diagnosis of AML in 22 patients was preceded by a myelodysplastic syndrome lasting more than six months; 8 of the 29 de novo AML cases (28%) were refractory to previous chemotherapy, 9 (31%) were treated for early relapse, 12 (41%) presented poor prognostic factors at diagnosis. The median age was 64 (range 33-76) years and the FAB subtypes were the following: M0 3, M1 5, M2 28, M4 7, M5 8. Forty-eight per cent of patients showed poor prognosis chromosomal abnormalities. FLAG (24 patients) consisted of both fludarabine 30 mg/sqm over 30 minutes followed 4 hours later by Ara-C 2 g/sqm over 4 hours (for 5 days) and G-CSF 300 micrograms/day administered 12 hours before fludarabine, for a total of 5 doses. FLANG (27 patients) had a shorter duration (3 days), reduced Ara-C dosage (1 g/sqm) and administration of mitoxantrone (10 mg/sqm) at the end of Ara-C infusion. RESULTS: Recovery of both neutrophils (PMN > 0.5 x 10(9)/L) and platelets (Plt > 20 x 10(9)/L) required a median of 16 days from the end of therapy. Overall, 30 patients (59%) achieved CR, 6 (11%) PR and 10 (20%) were refractory; 5 (10%) experienced early death (cerebral hemorrhage or infection). The length of complete response ranged from 2 to 26 months with a median follow-up of 8 months. De novo and secondary AML registered 62 and 54% CR rates, respectively. Eight out of 10 patients refractory to conventional schemes achieved CR (80%) but only 3 out of 10 treated for relapse obtained CR (30%). CONCLUSIONS: FLAG and FLANG showed similar activity and toxicity while proving to be highly effective and relatively well-tolerated treatments for high-risk de novo AML. Secondary leukemias seemed to be responsive as well, but the presence of an unfavorable karyotype alteration lowered the response rate.

Acute Disease↗
PubMedDate not supplied

Duplication of the der(13)t(12;13)(p13;q14) in chronic myelomonocytic leukemia.

A case of chronic myelomonocytic leukemia with a reciprocal translocation (12;13)(p13;q14) and other numerical and structural abnormalities is described. Most of the metaphases examined showed duplication of the der(13)t(12;13), leading to trisomy of the translocated segment of chromosome 12. Using fluorescence in situ hybridization we observed that the breakpoint on chromosome 13 is centromeric to the retinoblastoma gene. Since other cases with apparently similar t(12;13) have recently been reported, we conclude that this structural rearrangement may be a rare but non random event in hematologic disorders.

Aged↗
PubMedDate not supplied

Centralized cytogenetic analysis of pediatric acute leukemia: results of an Italian collaborative experience.

BACKGROUND AND OBJECTIVE: Cytogenetic analysis of acute leukemia yields important information which has been demonstrated to be correlated to patient survival. A reference laboratory was created in order to perform karyotype analysis on all cases of acute leukemia enrolled in the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica) protocols. METHODS: From January 1990 to December 1995, 1115 samples of children with ALL or AML were sent in for cytogenetic analysis. The results of cell cultures were screened in the Reference Laboratory and then the fixed metaphases were sent to one of the six cytogenetic laboratories for analysis. RESULTS: The leukemic karyotypes of 556 patients were successfully analyzed. An abnormal clone was detected in 49% of cases of ALL and in 66% of AML. In ALL the most frequent abnormality was 9p rearrangement. Other recurrent abnormalities were t(9;22), t(4;11) and t(1;19). In AML t(8;21), t(15;17) and 11q23 rearrangement were the most frequent structural abnormalities. These findings are similar to the results obtained in other multicenter studies using a similar approach. INTERPRETATION AND CONCLUSIONS: Our data confirm the feasibility of performing cytogenetic analysis in a centralized laboratory on mailed samples of bone marrow and/or peripheral blood; this is very important considering that cytogenetic analysis of neoplastic tissue requires a special laboratory and expert staff.

Acute Disease↗